NBIX vs. BMY
Compare and contrast key facts about Neurocrine Biosciences, Inc. (NBIX) and Bristol-Myers Squibb Company (BMY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NBIX or BMY.
Correlation
The correlation between NBIX and BMY is 0.26, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
NBIX vs. BMY - Performance Comparison
Key characteristics
NBIX:
0.14
BMY:
0.64
NBIX:
0.39
BMY:
1.21
NBIX:
1.06
BMY:
1.15
NBIX:
0.17
BMY:
0.38
NBIX:
0.36
BMY:
1.59
NBIX:
12.56%
BMY:
11.50%
NBIX:
32.84%
BMY:
28.42%
NBIX:
-97.21%
BMY:
-70.62%
NBIX:
-6.46%
BMY:
-23.68%
Fundamentals
NBIX:
$14.50B
BMY:
$114.17B
NBIX:
$3.78
BMY:
-$3.58
NBIX:
0.33
BMY:
1.94
NBIX:
$1.73B
BMY:
$35.96B
NBIX:
$1.69B
BMY:
$24.67B
NBIX:
$458.00M
BMY:
$605.00M
Returns By Period
In the year-to-date period, NBIX achieves a 4.95% return, which is significantly higher than BMY's 0.62% return. Over the past 10 years, NBIX has outperformed BMY with an annualized return of 16.07%, while BMY has yielded a comparatively lower 2.23% annualized return.
NBIX
4.95%
5.77%
-1.67%
4.76%
6.49%
16.07%
BMY
0.62%
1.09%
34.96%
17.95%
0.21%
2.23%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
NBIX vs. BMY — Risk-Adjusted Performance Rank
NBIX
BMY
NBIX vs. BMY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Neurocrine Biosciences, Inc. (NBIX) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
NBIX vs. BMY - Dividend Comparison
NBIX has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 4.30%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NBIX Neurocrine Biosciences, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
BMY Bristol-Myers Squibb Company | 4.30% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% | 2.46% |
Drawdowns
NBIX vs. BMY - Drawdown Comparison
The maximum NBIX drawdown since its inception was -97.21%, which is greater than BMY's maximum drawdown of -70.62%. Use the drawdown chart below to compare losses from any high point for NBIX and BMY. For additional features, visit the drawdowns tool.
Volatility
NBIX vs. BMY - Volatility Comparison
Neurocrine Biosciences, Inc. (NBIX) and Bristol-Myers Squibb Company (BMY) have volatilities of 5.90% and 5.82%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Financials
NBIX vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Neurocrine Biosciences, Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities